RECRUITING

Safety and Effectiveness of the Akura Thrombectomy System for Use in the Removal of Emboli From the Pulmonary Arteries in Treating Acute Pulmonary Embolism (PE)

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study is a prospective, single-arm, interventional, multicenter study to evaluate the safety and effectiveness of percutaneous mechanical thrombectomy using the Akura Thrombectomy System in subjects with acute pulmonary embolism (PE).

Official Title

Safety and Effectiveness of the Akura Thrombectomy System for Use in the Removal of Emboli From the Pulmonary Arteries in Treating Acute Pulmonary Embolism (PE)

Quick Facts

Study Start:2025-01-01

Study Completion:2025-12

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT06672510

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* The patient is 18 years of age or older and deemed medically eligible for interventional procedure, per institutional guidelines and clinical judgement * Clinical signs, symptoms and presentation consistent with acute PE * PE symptom duration ≤ 14 days * CTA evidence of proximal PE (filling defect in at least one main or lobar pulmonary artery) * CTA evidence of RV/LV ratio of ≥ 0.9 (NOTE: Enrollment qualification assessment is based on the Investigator's interpretation of RV/LV ratio at baseline) * Systolic BP ≥ 90 mmHg (initial SBP may be \< 90 mmHg but ≥ 80 mmHg if the pressure recovers with volume resuscitation) * Stable HR \< 130 BPM prior to the procedure	* Prior PE \<180 days from index procedure * Thrombolytic use within 30 days prior to baseline CTA * Pulmonary hypertension with peak pulmonary arterial pressure (PAP) \> 70 mmHg by right heart catheterization * Vasopressor requirement after fluids to keep pressure at ≥ 90 mmHg * FiO2 requirement \> 40% or \> 6 LPM (to keep oxygen saturation \> 90%) * Hematocrit \< 28% (Note: hematocrit required within 6 hrs. of index procedure) * Platelets \< 100,000/μL * eGFR \<30 ml/min per 1.73 m2 * International normalized ratio (INR) \> 3 * Major trauma injury severity score (ISS) \> 15 * Presence of intracardiac lead in right ventricle or atrium placed ≤ 6 months of enrollment * Cardiovascular or pulmonary surgery within the last 7 days * Actively progressing cancer treated by chemotherapeutics * Known bleeding diathesis or coagulation disorder * Left bundle branch block * History of severe or chronic pulmonary arterial hypertension * History of chronic left heart disease with left ventricular ejection fraction ≤ 30% * History of uncompensated heart failure. * History of underlying lung disease that is oxygen dependent * History of chest irradiation * History of heparin-induced thrombocytopenia (HIT) * Contraindication to systemic or therapeutic doses of anticoagulants * Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated * Known residual iliac deep vein thrombosis (DVT), inferior vena cava (IVC) clot or clot in transit (right atrium and/or right ventricle) * CTA imaging or other evidence that suggest, in the opinion of the investigator, the Subject is not appropriate for mechanical thrombectomy intervention (e.g. inability to navigate to target location, predominantly chronic clot or non-clot embolus) * Life expectancy \< 90 days, as determined by investigator (e.g., stage 4 cancer, frailty or severe COVID infections) * Female who is pregnant or nursing * Current participation in another investigational drug or device treatment study

Inclusion Criteria

Exclusion Criteria

* The patient is 18 years of age or older and deemed medically eligible for interventional procedure, per institutional guidelines and clinical judgement
* Clinical signs, symptoms and presentation consistent with acute PE
* PE symptom duration ≤ 14 days
* CTA evidence of proximal PE (filling defect in at least one main or lobar pulmonary artery)
* CTA evidence of RV/LV ratio of ≥ 0.9 (NOTE: Enrollment qualification assessment is based on the Investigator's interpretation of RV/LV ratio at baseline)
* Systolic BP ≥ 90 mmHg (initial SBP may be \< 90 mmHg but ≥ 80 mmHg if the pressure recovers with volume resuscitation)
* Stable HR \< 130 BPM prior to the procedure

* Prior PE \<180 days from index procedure
* Thrombolytic use within 30 days prior to baseline CTA
* Pulmonary hypertension with peak pulmonary arterial pressure (PAP) \> 70 mmHg by right heart catheterization
* Vasopressor requirement after fluids to keep pressure at ≥ 90 mmHg
* FiO2 requirement \> 40% or \> 6 LPM (to keep oxygen saturation \> 90%)
* Hematocrit \< 28% (Note: hematocrit required within 6 hrs. of index procedure)
* Platelets \< 100,000/μL
* eGFR \<30 ml/min per 1.73 m2
* International normalized ratio (INR) \> 3
* Major trauma injury severity score (ISS) \> 15
* Presence of intracardiac lead in right ventricle or atrium placed ≤ 6 months of enrollment
* Cardiovascular or pulmonary surgery within the last 7 days
* Actively progressing cancer treated by chemotherapeutics
* Known bleeding diathesis or coagulation disorder
* Left bundle branch block
* History of severe or chronic pulmonary arterial hypertension
* History of chronic left heart disease with left ventricular ejection fraction ≤ 30%
* History of uncompensated heart failure.
* History of underlying lung disease that is oxygen dependent
* History of chest irradiation
* History of heparin-induced thrombocytopenia (HIT)
* Contraindication to systemic or therapeutic doses of anticoagulants
* Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated
* Known residual iliac deep vein thrombosis (DVT), inferior vena cava (IVC) clot or clot in transit (right atrium and/or right ventricle)
* CTA imaging or other evidence that suggest, in the opinion of the investigator, the Subject is not appropriate for mechanical thrombectomy intervention (e.g. inability to navigate to target location, predominantly chronic clot or non-clot embolus)
* Life expectancy \< 90 days, as determined by investigator (e.g., stage 4 cancer, frailty or severe COVID infections)
* Female who is pregnant or nursing
* Current participation in another investigational drug or device treatment study

Contacts and Locations

Study Contact

Bryan Wylie

CONTACT

4085602500

clinicalaffairs@akuramed.com

Uday Illindala

CONTACT

4085602500

clinicalaffairs@akuramed.com

Study Locations (Sites)

Tristar Centennial Medical Center

Nashville, Tennessee, 37203

United States

Collaborators and Investigators

Sponsor: Akura Medical

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-01-01

Study Completion Date2025-12

Study Record Updates

Study Start Date2025-01-01

Study Completion Date2025-12

Terms related to this study

Additional Relevant MeSH Terms

Pulmonary Embolism Acute